Status:
COMPLETED
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Affective Psychosis, Bipolar
Mania
Eligibility:
All Genders
18+ years
Brief Summary
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
Detailed Description
Method: Consecutive patient sampling. Patients were included in the study in consecutive manner if they fulfilled the inclusion criteria and any of the exclusion criteria were not present.
Eligibility Criteria
Inclusion
- Manic and mixed episodes of up to moderate severity in patients with Type I and II bipolar disorder and schizoaffective disorder; either first diagnosed or repeated episodes
Exclusion
- Hypersensitivity to ziprasidone
- prolonged QTc interval
- coadministration with substances that are prolonging the QTc interval
- recent acute MI, cardiac failure, patients with arrhythmias treated with class IA or III medicaments
Key Trial Info
Start Date :
April 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
379 Patients enrolled
Trial Details
Trial ID
NCT00454883
Start Date
April 1 2007
End Date
December 1 2007
Last Update
February 21 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.